By PPN News Staff
Effective Dec. 31, 2019, evolocumab (Repatha, Amgen), will be distributed exclusively at the 60% lower list price of $5,850 per year and will no longer be available at its original list price.
Amgen introduced the lower list priced option of evolocumab in October 2018 to reduce out-of-pocket costs, especially for Medicare patients. However, to minimize disruption in the supply chain and allow time for payers and pharmacy benefit managers (PBMs) to modify existing contracts,